Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00801437 |
This study is designed to evaluate the safety and tolerability of Xalacom in patients with primary glaucoma
Condition | Intervention | Phase |
---|---|---|
Glaucoma, Open-Angle |
Drug: Xalacom |
Phase IV |
Study Type: | Observational |
Study Design: | Case-Only, Prospective |
Official Title: | Non Interventional Study in Slovak Patients With Primary Open Angle Glaucoma and/or Ocular Hypertension Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy Due to Ineffectivity or Intolerance. |
Estimated Enrollment: | 500 |
Study Start Date: | December 2008 |
Estimated Study Completion Date: | September 2009 |
Estimated Primary Completion Date: | September 2009 (Final data collection date for primary outcome measure) |
Groups/Cohorts | Assigned Interventions |
---|---|
Xalacom treatment
patients with primary glaucoma
|
Drug: Xalacom
Xalacom 1 drop into the affected eye daily
|
according to physicians decision, patients who met inclusion and exclusion criteria and sign the ICD
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Patients >18 years with primary open angle glaucoma or ocular hypertension
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Pfizer, Inc. ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | A6641053 |
Study First Received: | November 19, 2008 |
Last Updated: | December 9, 2008 |
ClinicalTrials.gov Identifier: | NCT00801437 |
Health Authority: | Slovakia: State Institute for Drug Control |
glaucoma, open-angle, non-interventional study, safety, tolerability |
Glaucoma Eye Diseases Glaucoma, Open-Angle |
Vascular Diseases Hypertension Ocular Hypertension |
Cardiovascular Diseases |